Palliative care and symptom relief for people affected by multidrug-resistant tuberculosis.


Journal

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
ISSN: 1815-7920
Titre abrégé: Int J Tuberc Lung Dis
Pays: France
ID NLM: 9706389

Informations de publication

Date de publication:
01 08 2019
Historique:
entrez: 20 9 2019
pubmed: 20 9 2019
medline: 18 4 2020
Statut: ppublish

Résumé

The World Health Organization (WHO) defines palliative care as the prevention and relief of the physical, psychological, social and spiritual suffering of adults and children with life-threatening illnesses and psycho-social support for their families. Palliative care and symptom relief (PCSR) also addresses suffering in nonlife-threatening situations such as after cure. PCSR should never be considered a substitute for tuberculosis (TB) prevention and treatment, but should be accessible by everyone in need. PCSR can reduce suffering and improve quality of life of patients with end-stage chronic illnesses while reducing costs for health care systems and providing financial risk protection for patients' families. It also may help enable patients to adhere to long and noxious treatments and thereby reduce mortality and help protect public health. Basic PCSR can be taught easily to TB specialists as well as primary care clinicians and delivered in hospitals, clinics or patients' homes combined with infection control. For these reasons, integration of PCSR into multidrug-resistant (MDR) and extensively drug-resistant TB (XDR-TB) treatment programs is medically and morally imperative. We propose an essential package of PCSR for people with M/XDR-TB that includes a set of safe, effective and inexpensive medicines and equipment, social supports for patients and caregivers living in extreme poverty, and necessary human resources. The package aligns with WHO guidance on programmatic management of drug-resistant (DR) TB and should be universally accessible by people affected by M/XDR-TB. We also describe the ethical practice of PCSR for people with M/XDR-TB and identify needed areas of research in PCSR for people with M/XDR-TB.

Identifiants

pubmed: 31533877
doi: 10.5588/ijtld.18.0428
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

881-890

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Auteurs

E L Krakauer (EL)

Division of Palliative Care and Geriatrics, Massachusetts General Hospital, Boston, Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

K Dheda (K)

University of Cape Town, Rondebosch, South Africa.

B Kalsdorf (B)

Forschungszentrum Borstel, Borstel, Germany.

L Kuksa (L)

Riga East University Hospital, Riga, Latvia.

A Nadkarni (A)

London School of Hygiene & Tropical Medicine, London, UK, Addictions Research Group, Goa, India.

N V Nhung (NV)

National Tuberculosis Control Program, Hanoi, National Lung Hospital, Hanoi, Vietnam.

P Selwyn (P)

Albert Einstein College of Medicine, New York, NY.

S Shin (S)

Partners In Health, Boston, MA, USA.

A Skrahina (A)

Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.

E Jaramillo (E)

Stop TB Department, World Health Organization, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH